Investigational drug · Phase 3
Cemdisiran
Also called: ALN-CC5
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Paroxysmal Nocturnal Hemoglobinuria, Generalized Myasthenia Gravis, Age-related Macular Degeneration (AMD).
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
4 still active
All registered trials
14
Any phase or sponsor naming "Cemdisiran"
First trial start
2021
Dec 14, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Cemdisiran", any sponsor or status.
Conditions studied
As listed on its trial records.
- Paroxysmal Nocturnal Hemoglobinuria
- Generalized Myasthenia Gravis
- Age-related Macular Degeneration (AMD)
- Geographic Atrophy (GA)
Approved drugs for the same conditions: Paroxysmal nocturnal hemoglobinuria · Myasthenia gravis · Wet macular degeneration · Geographic atrophy · Neurology · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "Cemdisiran" as an intervention, largest first.
- A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic AtrophyPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06541704 · 975 participants (planned) · Start Oct 30, 2024 · Primary completion Jul 31, 2028
Drug: Pozelimab; Cemdisiran and 1 more · For: Age-related Macular Degeneration (AMD); Geographic Atrophy (GA)
Sites: Chandler, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 233 sites in all
- A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia GravisPivotal-lookingActive, not recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT05070858 · 288 participants · Start Dec 14, 2021 · Primary completion Jul 8, 2025
Drug: Pozelimab + Cemdisiran; Cemdisiran and 1 more · For: Generalized Myasthenia Gravis
Sites: Scottsdale, Arizona; Irvine, California; Los Angeles, California · 116 sites in all
- A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it WorksPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT05744921 · 202 participants (planned) · Start Mar 7, 2023 · Primary completion Oct 10, 2028
Drug: Pozelimab; Cemdisiran · For: Paroxysmal Nocturnal Hemoglobinuria
Sites: Curitiba, Brazil; São Paulo, Brazil; Toronto, Canada · 50 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT05133531 · 202 participants · Start Aug 1, 2022 · Primary completion Sep 28, 2026
Drug: Ravulizumab; Pozelimab and 2 more · For: Paroxysmal Nocturnal Hemoglobinuria
Sites: Whittier, California; Santo André, Brazil; São Paulo, Brazil · 68 sites in all
- A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working EfficientlyPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07154745 · 35 participants (planned) · Start Jun 11, 2026 · Primary completion Jan 18, 2030
Drug: Pozelimab; Cemdisiran · For: Paroxysmal Nocturnal Hemoglobinuria
Sites: Ribeirão Preto, Brazil; Santo André, Brazil; São Paulo, Brazil · 20 sites in all
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT03841448 · 31 participants · Start Sep 30, 2019 · Primary completion Mar 17, 2022
Drug: Placebo; Cemdisiran · For: IgA Nephropathy (IgAN); Berger Disease; Glomerulonephritis, IgA
Sites: Vancouver, Canada; Brampton, Canada; Toronto, Canada · 17 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT04940364 · 30 participants · Start Aug 4, 2021 · Primary completion Jun 22, 2022
Drug: Pozelimab; Cemdisiran · For: Healthy
Sites: London, United Kingdom
Regeneron PharmaceuticalsRegeneron (REGN)
NCT04811716 · 24 participants · Start Jul 29, 2021 · Primary completion Oct 25, 2022
Drug: Pozelimab; Cemdisiran · For: Paroxysmal Nocturnal Hemoglobinuria
Sites: Hong Kong, Hong Kong; Budapest, Hungary; Miri, Malaysia · 13 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT04601844 · 19 participants · Start Nov 16, 2020 · Primary completion Jul 23, 2021
Drug: Pozelimab; Cemdisiran · For: Healthy
Sites: Antwerp, Belgium
Regeneron PharmaceuticalsRegeneron (REGN)
NCT04888507 · 6 participants · Start Jul 8, 2021 · Primary completion May 5, 2022
Drug: Pozelimab; Cemdisiran · For: Paroxysmal Nocturnal Hemoglobinuria
Sites: Leeds, United Kingdom
Newest research
PubMed records naming it or its code names, newest first.
- Current and Emerging Therapies for Generalized Myasthenia Gravis: Toward Precision Medicine.
Yoshikawa M, Ide T, Koike H · Neurol Ther 2026
- Mapping the complement-targeted landscape in igA nephropathy: a systematic review with structured descriptive synthesis.
Li XY, Zhong CY, Zhang LN, et al. · Front Med (Lausanne) 2026
- Another complement inhibitor therapy for myasthenia gravis: Is it NIMBLE enough?
Kusner LL, Kaminski HJ · Med 2026
- Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trial.
Vu T, Habib AA, Jacob S, et al. · Lancet 2026
- Emerging Therapies in IgA Nephropathy: From A Proliferation-Inducing Ligand (APRIL) and B-cell Activating Factor (BAFF) Inhibitors to Precision Medicine.
Sharma I, Panta R · Cureus 2025
- Pharmacological Therapies in Paroxysmal Nocturnal Haemoglobinuria: Focus on Complement Inhibition.
Kelly RJ, Holt M, Szer J · Drugs 2025
Also in development for Paroxysmal Nocturnal Hemoglobinuria
- HRS-5965Phase 36 trials
Chengdu Suncadia Medicine Co., Ltd. · Primary IgA Nephropathy, Paroxysmal Nocturnal Hemoglobinuria
- HSK39297Phase 35 trials
Haisco Pharmaceutical Group Co., Ltd. · IgA Nephropathy (IgAN), Paroxysmal Nocturnal Hemoglobinuria, Paroxysmal Nocturnal Haemoglobinuria (PNH)
- MY008211APhase 35 trials
Wuhan Createrna Science and Technology Co., Ltd · Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Nocturnal Hemoglobinuria, IgA Nephropathy (IgAN)
- FXS6837Phase 34 trials
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Paroxysmal Nocturnal Hemoglobinuria, Primary IgAN, IgAN
- NTQ5082Phase 34 trials
Nanjing Chia-tai Tianqing Pharmaceutical · Paroxysmal Nocturnal Hemoglobinuria, Primary IgA Nephropathy
- NM8074Phase 28 trials
NovelMed Therapeutics · Paroxysmal Nocturnal Hemoglobinuria, Dermatomyositis, PNH - Paroxysmal Nocturnal Hemoglobinuria
- LP-005Phase 24 trials
Longbio Pharma · Periodontitis, Paroxysmal Nocturnal Hemoglobinuria, Complement-mediated Renal Diseases
- HS-10542Phase 22 trials
Jiangsu Hansoh Pharmaceutical Co., Ltd. · IgAN, Immunoglobulin A Nephropathy (IgAN), Glomerular Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Regeneron.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.